Phase 3 · NCT07035093
TRIUMPH-7
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- TRIUMPH-7
- ClinicalTrials.gov ID
- NCT07035093
- Indication
- Obesity, Overweight, Chronic Low Back Pain (CLBP)
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 586
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 40 sites · Argentina, Canada, Poland, United States
- Study start
- 29 May 2025
- Primary completion
- 1 Sept 2027
- Study completion
- 1 Sept 2027
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 25 Sept 2026
Endpoints
Primary
Change from Baseline in Pain Intensity Per Numeric Rating Scale; Percent Change from Baseline in Body Weight
Secondary
Number of Participants with Reduction in Pain Intensity Per Numeric Rating Scale; Number of Participants with Reduction in Body Weight; Change in Physical Function as Measured by Patient-Reported Outcomes Measurement Information Systems (PROMIS); Change in Pain Interference as Measured by PROMIS; Change in Sleep as Measured by PROMIS; Change in Patient Reported Health Outcomes as Measured by Medical Outcomes Study 36-item Short Form Health Survey version 2 (SF-36v2); Change in Waist Circumference; Change in Biomarkers of Inflammation as Measured by Blood Test; Change in Blood Pressure; Change in Glycemic Control; Percent Change in Total Cholesterol; Percent Change in Urine Albumin-to-Creatinine Ratio (UACR)